Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Lumiracoxib (drug)
Lumiracoxib · 8 trials · 5 indications
| Name | Type | Description |
|---|---|---|
| Lumiracoxib (drug) | DRUG | - |
| Lumiracoxib | DRUG | - |
Inclusion Criteria: * Diagnosis of primary hip osteoarthritis * Qualifying pain intensity in the hip joint * Requiring NSAID therapy Exclusion Criteria: * Rheumatoid arthritis or other inflammatory joint disease * Disease or disorder that may interfere with pain assessment of the hip * Open knee/...
Top 5 of 14 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 4 | PHASE3 | Orforglipron, Eloralintide, LY3016859, LY3556050, LY3526318 |
| Pacira Biosciences, Inc. | PCRX | 4 | PHASE3 | ZILRETTA, Enekinragene Inzadenovec, FX201 |
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 2 | PHASE3 | NNC0487-0111 |
| Bioventus, Inc. Class A | BVS | 1 | PHASE2 | PTP-001 |
| Enlivex Ltd. | ENLV | 2 | PHASE1 | Allocetra |
Lumiracoxib is being studied for the treatment of osteoarthritis, including primary knee osteoarthritis and hip osteoarthritis. It is a small molecule developed by Novartis AG. The clinical program focuses on musculoskeletal conditions, with trials enrolling adults aged 18 years and older.
Lumiracoxib targets PTGS2, also known as cyclooxygenase-2 (COX-2). It acts as an inhibitor of this enzyme. By inhibiting PTGS2, the drug is designed to reduce inflammation and pain associated with osteoarthritis. This mechanism is characteristic of the COX-2 inhibitor class.
Lumiracoxib is developed by Novartis AG, which trades under the ticker NVS. Novartis is the sponsor of the clinical trials investigating the drug for osteoarthritis. The company holds the development program for this small molecule.
Lumiracoxib is in Phase 3 clinical development. It has completed five Phase 3 trials with a total enrollment of 5,646 participants. These trials were randomized and double-blind, evaluating the efficacy and safety of the drug in patients with knee osteoarthritis.
Lumiracoxib has been studied in several completed Phase 3 trials, including NCT00476034, NCT00475800, NCT00367315, and NCT00366938. These trials assessed efficacy and safety in primary knee osteoarthritis across multiple countries, with enrollment ranging from 833 to 1,684 participants per study.
Yes, Lumiracoxib (drug) is an alternative name for Lumiracoxib. Both refer to the same investigational small molecule developed by Novartis AG for osteoarthritis. The parenthetical qualifier is sometimes used to distinguish the pharmaceutical agent in database entries.